报价延迟最少15分钟:2026/07/20 02:57 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.2292 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.83/-0.81
|
|
企业价值
10.10M
|
| 资产负债 |
|
每股账面净值
0.87
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
1.27M
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mentalfatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders. |
